Remix Therapeutics
Remix Therapeutics, established in 2020, focuses on transforming patients' lives by developing small molecule therapies to modulate RNA processing and address disease drivers. The company utilizes its proprietary REMaster™ platform and has a broad pipeline, including REM-422, which is in Phase 1 clinical trials for treating ACC and AML/MDS.
Company Overview
Remix Therapeutics launched in 2020 with a vision to transform patients' lives by modulating RNA processing. The company develops small molecule therapies that address the underlying drivers of various diseases by targeting RNA processing. Located in Watertown, USA, Remix Therapeutics leverages its proprietary REMaster™ drug discovery platform to identify and develop innovative treatments.
Proprietary Technology - REMaster™ Platform
The REMaster™ platform is at the core of Remix Therapeutics' approach to drug development. This proprietary platform identifies druggable target sites and active chemical matter for creating new medicines. Utilizing an extensive transcriptome database and machine learning, the platform helps discover modulatable sites across various target areas. Over 1.6 million novel exon targets in the mRNA degradation space have been identified, and a proprietary genetic toolkit validates that these targets can be modulated to achieve desired gene and protein expression outcomes.
REM-422: Lead Clinical Candidate
REM-422 is Remix Therapeutics’ lead candidate, currently in Phase 1 clinical trials. This oral small molecule mRNA degrader is being explored for treating Adenoid Cystic Carcinoma (ACC) and Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS). REM-422 has received Orphan Drug Designation from the FDA for these indications. The molecule targets the MYB transcription factor, promoting the incorporation of poison exons within the mRNA transcript, leading to nonsense-mediated decay and reduction of MYB mRNA and protein expression, demonstrating antitumor activity in MYB-dependent models.
Collaborations and Partnerships
Remix Therapeutics has established significant partnerships to bolster its research and development efforts. The company announced a collaboration and license agreement with Roche to discover and develop small molecule therapeutics that modulate RNA processing. Additionally, Remix has a multi-year, three-target strategic collaboration with Johnson & Johnson Innovation Medicine, formerly known as Janssen. These partnerships aim to enhance the development of groundbreaking treatments.
Pipeline and Clinical Programs
Remix Therapeutics has a broad pipeline of RNA processing modulators targeting Oncology and Neurodegeneration. The development programs are crafted by industry experts and informed by patient and clinician insights to create impactful therapies. The company has rapidly advanced multiple drug discovery programs towards clinical stages, driven by their extensive chemical library and proprietary technologies aimed at exploiting RNA processing for therapeutic benefits.